Related Experiment Video
Updated: Feb 15, 2026

Novel Diagnostics in Revision Arthroplasty: Implant Sonication and Multiplex Polymerase Chain Reaction
Published on: December 3, 2017
Economic analysis of rapid multiplex polymerase chain reaction testing for meningitis/encephalitis in pediatric
Steve Duff1, Rodrigo Hasbun2, Christine C Ginocchio3,4,5
1Veritas Health Economics Consulting, Carlsbad, CA, USA.
Insights
Rapid syndromic testing for pediatric meningitis/encephalitis is cost-effective. Testing all suspected cases with FilmArray® (FA) offers greater economic benefits compared to standard care or targeted testing.
Area of Science:
- Infectious Diseases
- Health Economics
- Pediatric Medicine
Background:
- Community-acquired meningitis/encephalitis in children poses diagnostic challenges.
- Standard diagnostic procedures can be time-consuming and costly.
- Rapid diagnostic tools are needed to improve patient outcomes and resource allocation.
Purpose of the Study:
- To evaluate the economic impact of a rapid syndromic testing strategy for pediatric patients with suspected meningitis/encephalitis.
- To compare the costs of standard care (SOC) with FilmArray® (FA) testing strategies.
Main Methods:
- A cost-effectiveness model was developed to simulate diagnosis and clinical decisions.
- Two cerebrospinal fluid (CSF) testing strategies using FilmArray® (FA) were compared to SOC.
- Resource utilization and associated costs were analyzed.
Main Results:
- FilmArray® (FA) accurately diagnosed 97% of pathogens causing approximately 75% of cases.
- Mean cost per case ranged from $17,599 to $22,025.
- Syndromic testing of all suspected cases yielded greater savings ($3481/case) than targeted testing ($2157/case) or SOC.
Conclusions:
- Syndromic testing using FilmArray® (FA) for all suspected pediatric meningitis/encephalitis cases is more cost-effective than SOC.
- Targeted syndromic testing offers savings but less than universal syndromic testing.
- Implementing rapid syndromic testing can lead to significant economic benefits in pediatric infectious disease diagnostics.
Aim:
We assessed the possible economic impact of a rapid test in pediatric patients with suspected community-acquired meningitis/encephalitis.
Materials & Methods:
Modeling simulated diagnosis, clinical decisions, resource use/costs of standard of care (SOC) and two cerebrospinal fluid testing strategies using FilmArray® (FA), a US FDA-cleared system that provides results in approximately 1 h.
Results:
Pathogens detected by FA caused approximately 75% of cases, 97% of which would be accurately diagnosed with FA. Mean cost/case ranged from $17,599 to $22,025. Syndromic testing is less expensive than SOC. Testing all suspected cases yielded greater savings ($3481/case) than testing only those with abnormal cerebrospinal fluid ($2157/case).
Conclusion:
Greater economic benefits are achievable with syndromic testing of all cases, rather than SOC or targeted syndromic testing.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pharmacokinetics in Pediatric Patients: Drug Distribution
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Translesion DNA Polymerases
TLS polymerases are found in all three domains of life - archaea, bacteria, and eukaryotes. Of the different classes of TLS polymerases, members of the Y family are fitted with specialized structures that...
Bacterial RNA Polymerase
In most genes, the transcription site is a single base present upstream of the coding sequence. Though RNAP is a catalytically efficient enzyme, it does not recognize...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

